EOLS
Evolus Inc.
$6.85
+$0.23(+3.47%)
33
Overall
40
Value
27
Tech
--
Quality
Market Cap
$455.68M
Volume
1.22M
52W Range
$5.71 - $17.12
Target Price
$19.60
Company Overview
| Mkt Cap | $455.68M | Price | $6.85 |
| Volume | 1.22M | Change | +3.47% |
| P/E Ratio | -9.0 | Open | $6.56 |
| Revenue | $266.3M | Prev Close | $6.62 |
| Net Income | $-50.4M | 52W Range | $5.71 - $17.12 |
| Div Yield | N/A | Target | $19.60 |
| Overall | 33 | Value | 40 |
| Quality | -- | Technical | 27 |
No chart data available
About Evolus Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest News
Evolus (EOLS) Receives a Buy from Mizuho Securities
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EOLS | $6.85 | +3.5% | 1.22M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |